Early vs. standard zoledronic acid to prevent skeletal related events in prostate cancer

eagle-i ID

Resource Type

Properties

1. Intervention

   Zoledronate

2. Additional Topic(s)

   Bone fractures

3. Additional Topic(s)

   Drug administration schedule

4. Resource Description

   This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases. Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   prostate cancer

8. Study Population

   Men at least 18 years old, more than 1 year since hormone therapy that lasted no more than 6 months, and no more than 3 months since starting current androgen deprivation therapy. At least 4 weeks since radiation therapy. No previous bisphosphonates (such as zoledronate).

9. Funded by

   Cancer Trials Support Unit

10. Phase

    Phase 3 clinical trial

11. Performed by

    Clinical Protocol & Data Management Shared Resource